about
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patientsPharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaThe epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsPopulation pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVEffects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary TuberculosisThe pyrazinamide susceptibility breakpoint above which combination therapy fails.Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional studyEffects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Research capacity. Enabling the genomic revolution in Africa.Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimenDeterminants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited settingRandomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapyPharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Reply to "breakpoints and drug exposure are inevitably closely linked"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Population pharmacokinetics of ethambutol in South African tuberculosis patients.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for childrenTowards early inclusion of children in tuberculosis drugs trials: a consensus statementPharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study
P50
Q28469076-5C6E4438-5CA5-466A-B100-35ADCF0FBE75Q28550488-E6F37DB2-0CED-42F7-ABA1-8E68116B4A2EQ30235074-CB63A341-FFE5-467E-B134-EDB429D0DE29Q31041943-24681889-0A65-46B1-8CFC-82721CF8EB65Q33364134-DB676E66-B1AC-4E10-B2FA-E060CC27212FQ33433684-F29F7834-0ADC-45CF-B645-0502E1A137BCQ33547682-6C56C0FD-4EC5-4352-B8E3-DEF2AC4C99CBQ33605816-C012F19A-7A91-42F3-A135-96471423AFC3Q33621748-28C06E19-42D3-43FF-BBAB-95318642BC50Q33725030-EAE0B4A2-7031-49B0-B02A-566CB1F27A5EQ33797999-FA41EBCC-F188-49F5-AB3F-8D12991EC03BQ33843675-382C6A0D-80CF-4D6B-89E9-80944595D1A4Q34034401-114761A7-07A4-4B47-B8ED-FAD3CDD007F9Q34039225-646F6C2F-5DC7-4F32-B90D-329073447933Q34045240-9A3F2078-ACBD-4F43-999E-F06C850C581EQ34068017-BF6B824D-E4C4-4228-9EC7-E781B896F1B2Q34123784-5CDAA245-CDDC-40FD-B05D-93A9BDDE2CA7Q34193050-AE334ED1-3A7C-48AA-991A-04269CF2F531Q34251459-F2278E39-E795-41E6-B8F9-DBD3C9D9CC4EQ34298988-301CFD60-873B-4822-83A5-2B9AEF2676FBQ34455442-79545451-CAF1-442D-B321-FF83D6D0E0C0Q34498914-D6C8385D-7958-47FC-9F03-BB983E83F811Q34510679-CF744462-11A1-470E-86E9-BEA9924E9BC9Q34519945-C896BB0D-BF0A-47BA-8F67-FD2CEC5F6079Q34778123-9E84332A-4DAC-447E-8726-D6BA37FC9A3CQ34778531-F17EF73E-D285-4A5B-ACAB-A43E9C13552FQ34920590-67F8C7B1-0538-405B-B135-CC43E5F71E29Q34922554-BA54DA20-9B3E-49D3-802A-25681A56CCDDQ35065871-875BC19C-973C-4124-8D56-216966055F58Q35093189-4AF44878-5CB1-4C52-8558-C3B317681619Q35106037-3A4C5177-1F9E-4E42-82F8-F5F107DD72ECQ35120591-3B83DC78-1905-4311-9C97-A2EC9CF3BCF4Q35191432-5BA03F36-39C2-4E28-B972-9A50E3925E67Q35191463-2BE6699B-034C-4663-9FEE-1642DB9F106DQ35197257-131015E4-07DB-4C40-90A6-7C8F01D6347CQ35742101-021D9638-9318-4E9B-980D-2AB3A291A14FQ35752740-D3EBE4FD-7A62-4A29-97B4-7794993E0C0BQ35846143-4BB8504A-1FAC-4A13-A771-2FEB970FF055Q35867335-5D79D8A9-25EA-4DDE-A2A0-5BF0EA8CF40EQ35974648-ECCB33A4-FA64-4329-9166-FA01606B9C9D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Helen McIlleron
@ast
Helen McIlleron
@en
Helen McIlleron
@es
Helen McIlleron
@nl
Helen McIlleron
@sl
type
label
Helen McIlleron
@ast
Helen McIlleron
@en
Helen McIlleron
@es
Helen McIlleron
@nl
Helen McIlleron
@sl
prefLabel
Helen McIlleron
@ast
Helen McIlleron
@en
Helen McIlleron
@es
Helen McIlleron
@nl
Helen McIlleron
@sl
P106
P1153
16426027000
P21
P31
P496
0000-0002-0982-6226